Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up

Highlights • Patients with splanchnic vein thrombosis have a high risk of thrombotic and bleeding events. • Anticoagulant treatment significantly promotes thrombus resolution. • Solid cancer and hypoalbuminemia were associated with a worse survival.

Saved in:
Bibliographic Details
Published inThrombosis research Vol. 154; pp. 55 - 58
Main Authors Jara-Palomares, Luis, Marin-Barrera, Lucia, Giraldez-Gallego, Alvaro, Garzon-Benavides, Marta, Elias-Hernández, Teresa, Praena-Fernandez, Juan Manuel, Asensio-Cruz, Maria Isabel, Solier-Lopez, Aurora, Suarez-Valdivia, Lionel, Sanchez-Diaz, Jose Maria, Otero-Candelera, Remedios
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.06.2017
Subjects
Female
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Hemorrhage - drug therapy
Hemorrhage - etiology
Heparin
Humans
Male
Middle Aged
Splanchnic Circulation - drug effects
Splanchnic vein thrombosis
Thrombosis - drug therapy
Vitamin K antagonist
Splanchnic vein thrombosis
Vitamin K antagonist
Heparin
Online AccessGet full text

Cover

More Information
Summary:Highlights • Patients with splanchnic vein thrombosis have a high risk of thrombotic and bleeding events. • Anticoagulant treatment significantly promotes thrombus resolution. • Solid cancer and hypoalbuminemia were associated with a worse survival.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2017.03.028